GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Beneish M-Score

Sino Biopharmaceutical (FRA:SMZ1) Beneish M-Score : -2.73 (As of Dec. 13, 2024)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.73 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sino Biopharmaceutical's Beneish M-Score or its related term are showing as below:

FRA:SMZ1' s Beneish M-Score Range Over the Past 10 Years
Min: -3.39   Med: -2.14   Max: -0.35
Current: -2.73

During the past 13 years, the highest Beneish M-Score of Sino Biopharmaceutical was -0.35. The lowest was -3.39. And the median was -2.14.


Sino Biopharmaceutical Beneish M-Score Historical Data

The historical data trend for Sino Biopharmaceutical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Beneish M-Score Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.39 -2.07 -1.11 -2.77 -2.73

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.77 - -2.73 -

Competitive Comparison of Sino Biopharmaceutical's Beneish M-Score

For the Biotechnology subindustry, Sino Biopharmaceutical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Beneish M-Score falls into.



Sino Biopharmaceutical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sino Biopharmaceutical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9902+0.528 * 1.0223+0.404 * 1.0424+0.892 * 0.9548+0.115 * 1.0397
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9389+4.679 * -0.058703-0.327 * 0.9895
=-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €796 Mil.
Revenue was €3,365 Mil.
Gross Profit was €2,724 Mil.
Total Current Assets was €3,057 Mil.
Total Assets was €8,169 Mil.
Property, Plant and Equipment(Net PPE) was €1,273 Mil.
Depreciation, Depletion and Amortization(DDA) was €138 Mil.
Selling, General, & Admin. Expense(SGA) was €1,421 Mil.
Total Current Liabilities was €2,903 Mil.
Long-Term Debt & Capital Lease Obligation was €176 Mil.
Net Income was €299 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €779 Mil.
Total Receivables was €842 Mil.
Revenue was €3,524 Mil.
Gross Profit was €2,916 Mil.
Total Current Assets was €3,512 Mil.
Total Assets was €8,675 Mil.
Property, Plant and Equipment(Net PPE) was €1,253 Mil.
Depreciation, Depletion and Amortization(DDA) was €142 Mil.
Selling, General, & Admin. Expense(SGA) was €1,585 Mil.
Total Current Liabilities was €2,728 Mil.
Long-Term Debt & Capital Lease Obligation was €577 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(796.074 / 3364.732) / (842.042 / 3524.061)
=0.236594 / 0.238941
=0.9902

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2916.418 / 3524.061) / (2723.893 / 3364.732)
=0.827573 / 0.809542
=1.0223

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3057.291 + 1272.997) / 8168.625) / (1 - (3511.705 + 1252.652) / 8674.596)
=0.469888 / 0.450769
=1.0424

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3364.732 / 3524.061
=0.9548

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(141.766 / (141.766 + 1252.652)) / (137.968 / (137.968 + 1272.997))
=0.101667 / 0.097783
=1.0397

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1421.263 / 3364.732) / (1585.422 / 3524.061)
=0.4224 / 0.449885
=0.9389

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((176.308 + 2903.338) / 8168.625) / ((576.569 + 2728.494) / 8674.596)
=0.377009 / 0.381005
=0.9895

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(299.486 - 0 - 779.009) / 8168.625
=-0.058703

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sino Biopharmaceutical has a M-score of -2.76 suggests that the company is unlikely to be a manipulator.


Sino Biopharmaceutical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines